(Q44314898)

1 December 2017

Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model (English)

1 reference

1 December 2017

1 reference

Franck Le Guerhier

1

1 reference

1 December 2017

Alexandre Thermet

2

1 reference

1 December 2017

Sylvianne Guerret

3

1 reference

1 December 2017

Michèle Chevallier

4

1 reference

1 December 2017

Catherine Jamard

5

1 reference

1 December 2017

Craig S Gibbs

6

1 reference

1 December 2017

Christian Trépo

7

1 reference

1 December 2017

Lucyna Cova

8

1 reference

1 December 2017

Fabien Zoulim

9

1 reference

1 December 2017

1 March 2003

1 reference

1 December 2017

Journal of Hepatology

1 reference

1 December 2017

38

1 reference

1 December 2017

3

1 reference

1 December 2017

328-334

1 reference

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Identification of major antigenic domains of duck hepatitis B virus pre-S protein by peptide scanning

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Fine mapping of neutralization epitopes on duck hepatitis B virus (DHBV) pre-S protein using monoclonal antibodies and overlapping peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

Therapeutic applications of CpG-containing oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900425-7

7 January 2021

10.1016/S0168-8278(02)00425-7

Identifiers

DOI

1 reference

1 December 2017

1 reference